Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study

Authors

Hiroshi Nakase (ORCID: https://orcid.org/0000-0003-2848-6586)
Oh Kyu Yoon (ORCID: https://orcid.org/0009-0007-9256-7192)
Alessandra Oortwijn (ORCID: https://orcid.org/0000-0002-8556-1004)
Walter Reinisch (ORCID: https://orcid.org/0000-0002-2088-091X)
Toshifumi Hibi∥ (ORCID: https://orcid.org/0000-0002-6256-1204)
Yuan Tian (ORCID: https://orcid.org/0000-0003-0192-3037)
Yasmina Bauer
Silvio Danese (ORCID: https://orcid.org/0000-0001-7341-1351)
Emmanuel Karouzakis (ORCID: https://orcid.org/0000-0001-7650-9653)
Barrett G. Levesque
Toshihiko Kaise (ORCID: https://orcid.org/0000-0001-6059-7900)
Yan Liang (ORCID: https://orcid.org/0000-0002-6972-2541)
Emily Wendt
Vladislav A. Malkov
Timothy E. Ritter
Luting Zhuo

Institutions

Sapporo Medical University (JP)
Gilead Sciences (United States) (US)
Galapagos (Netherlands) (NL)
Kitasato Institute Hospital (JP)
IRCCS Humanitas Research Hospital (IT)
Kitasato University (JP)
Medical University of Vienna (AT)
Galapagos (Belgium) (BE)

Publication Details

Journal: Inflammatory Bowel Diseases
Published: 2024-12-04
DOI: https://doi.org/10.1093/ibd/izae278
Citations: 3
Primary Topic: Inflammatory Bowel Disease
Type: article
Field-Weighted Citation Impact: 1.65

Funders

Gilead Sciences
EA Pharma Co., Ltd.
Galápagos
Eisai

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study

Hiroshi Nakase, Oh Kyu Yoon, Alessandra Oortwijn, Walter Reinisch et al.

Dec 4, 2024

3 citations

Inflammatory Bowel Diseases

Inflammatory Bowel Disease

1.65

article

Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study

Hiroshi Nakase, Oh Kyu Yoon, Alessandra Oortwijn, Walter Reinisch, Toshifumi Hibi∥, Yuan Tian, Yasmina Bauer, Silvio Danese, Emmanuel Karouzakis, Barrett G. Levesque, Toshihiko Kaise, Yan Liang, Emily Wendt, Vladislav A. Malkov, Timothy E. Ritter, Luting Zhuo

December 4, 2024article en

3 citations

Abstract

No abstract available for this paper.

Inflammatory Bowel DiseasesVol. 31(4)

Sapporo Medical University (JP), Gilead Sciences (United States) (US), Galapagos (Netherlands) (NL), Kitasato Institute Hospital (JP), IRCCS Humanitas Research Hospital (IT), Kitasato University (JP), Medical University of Vienna (AT), Galapagos (Belgium) (BE)

Gilead Sciences, EA Pharma Co., Ltd., Galápagos, Eisai

Good health and well-being

Openalex Percentile: Top 14%

Inflammatory Bowel Disease

1.65

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.